First, we tested the stability of K17 in KCs upon treatment with the protein synthesis inhibitor cycloheximide (CHX) in control, Pso Mix-treated, and ENO1 siRNA-treated HaCaT cells. Here, KRT17 is linked to dry eye syndrome.